Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia

Completed · Phase 3

Conditions studied: Leukemia

In brief

RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining interferon alfa with high-dose chemotherapy and peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of interferon alfa with or without peripheral stem cell transplantation in treating patients who have newly diagnosed chronic myelogenous leukemia in chronic phase.

Key facts

Study ID

NCT00002868

Run by

Eastern Cooperative Oncology Group

People needed

744

Starts

1997-11-20

Last updated by the study team

2023-06-22

Who can join

Age: 15 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Hackensack University Medical Center — Hackensack, New Jersey, United States
• Riverview Medical Center - Booker Cancer Center — Red Bank, New Jersey, United States
• Royal Infirmary — Glasgow, Scotland, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.